- Advertisement -
TAG
GSK
Hibsago approved as first antisense hep B therapy
GSK's Hibsago (bepirovirsen) is the first antisense therapy FDA-approved for chronic hepatitis B, with a 19% functional cure rate in Phase 3 trials.
- Advertisement -
16.1
C
New York
Saturday, October 24, 2026
© Trends News Stories , LLC. All rights reserved. Trends News Stories ® is a registered U.S. trademark of News Publication and Media Company.